Sermorelin Peptide: Research Profile — FDA-Approved GHRH Analog for GH Deficiency

What Is Sermorelin?

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino-acid endogenous growth hormone-releasing hormone (GHRH). Also designated GRF(1-29)-NH₂, it represents the minimum bioactive fragment of GHRH that fully activates the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells. With a molecular weight of approximately 3357.96 Da and a sequence of Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂, sermorelin is the shortest GHRH analog that retains complete biological activity.

For dosing, reconstitution, and protocol details, see our Sermorelin Dosage Guide: Research Protocol, Reconstitution & GHRH Timing (2026).

Sermorelin was the first GHRH analog to receive FDA approval, marketed under the brand name Geref Diagnostic for evaluating pituitary GH secretory capacity. It occupied a foundational position in growth hormone research before longer-acting modified analogs like CJC-1295 and Tesamorelin were developed. Understanding sermorelin's pharmacology, research history, and mechanistic profile remains essential for anyone working within the growth hormone secretagogue field.

Structural Biology and Molecular Identity

Primary Structure

The endogenous human GHRH is a 44-amino-acid peptide (GHRH 1-44) produced by hypothalamic neurons in the arcuate nucleus. Early structure-activity relationship (SAR) studies in the 1980s established that the N-terminal 29 amino acids — now called sermorelin or GRF(1-29) — retained full receptor binding affinity and intrinsic activity at the GHRH-R. The C-terminal residues 30-44 of full-length GHRH primarily contribute to metabolic stability and receptor binding affinity fine-tuning, but are not required for bioactivity.

The amide group at the C-terminus (–NH₂ rather than the free carboxyl –COOH) is critical for receptor recognition. Deamidated sermorelin (the free acid form) shows markedly reduced potency, underscoring the importance of this modification in synthetic production.

Key structural identifiers for research documentation:

• •CAS number: 86168-78-7
• •Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• •Molecular weight: 3357.96 Da
• •IUPAC Name: L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide
• •Peptide bond count: 28
• •Disulfide bonds: None

Comparison to Full-Length GHRH(1-44)

Endogenous GHRH(1-44) has a half-life measured in seconds to minutes in plasma due to rapid N-terminal cleavage by dipeptidyl peptidase IV (DPP-IV) at the Tyr¹-Ala² bond. Sermorelin shares this vulnerability, making both peptides highly dependent on pulsatile delivery to mimic physiological GHRH dynamics. This pharmacokinetic constraint became the primary motivation for developing analogs with substitutions at position 2 (such as D-Ala² in modified CJC peptides) to resist DPP-IV cleavage.

Mechanism of Action

GHRH Receptor Activation

Sermorelin binds with high affinity to the GHRH receptor (GHRH-R), a member of the class B (secretin-like) G-protein-coupled receptor (GPCR) family. The GHRH-R is expressed predominantly on anterior pituitary somatotroph cells, which constitute approximately 35-45% of the anterior pituitary cell population.

Upon binding, sermorelin activates the Gαs protein subunit, which stimulates adenylyl cyclase to convert ATP to cyclic AMP (cAMP). The rise in intracellular cAMP activates protein kinase A (PKA), which phosphorylates and activates the CREB (cAMP response element-binding protein) transcription factor. CREB then drives transcription of the GH gene (GH1), leading to increased GH synthesis. Simultaneously, the cAMP signal activates voltage-gated calcium channels, triggering exocytosis of GH-containing secretory granules into the portal circulation.

The downstream signaling cascade proceeds as follows:

1. Sermorelin → GHRH-R binding (nanomolar affinity at the receptor)

2. Gαs activation → adenylyl cyclase stimulation

3. cAMP elevation → PKA activation

4. PKA → CREB phosphorylation → GH1 gene transcription

5. cAMP → Ca²⁺ channel gating → GH granule exocytosis

6. GH enters portal circulation → hepatic IGF-1 production

7. IGF-1 → negative feedback inhibition of GH/GHRH

This pathway preserves the physiological regulatory architecture. Because sermorelin operates through the hypothalamic-pituitary axis rather than directly introducing exogenous GH, the somatostatin-mediated negative feedback and IGF-1 feedback loops remain intact, constraining GH release within physiological bounds.

Preservation of Pulsatile GH Secretion

A defining feature of sermorelin's mechanism is its support for pulsatile — rather than continuous — GH release. Under physiological conditions, GH is secreted in pulses every 3-5 hours, driven by alternating hypothalamic GHRH and somatostatin signals. These pulses are biologically significant: hepatic GH receptors, adipocyte lipolysis pathways, and muscle IGF-1 production are all more responsive to pulsed GH delivery than to continuous elevated GH levels.

Sermorelin's short half-life (approximately 10-20 minutes) means that subcutaneous injection produces a transient GHRH-R stimulus, evoking a brief GH pulse that dissipates as sermorelin is cleared. This pulse dynamic closely recapitulates the physiological GH secretion pattern, which may explain why sermorelin avoids the receptor desensitization observed with sustained GHRH receptor agonism from long-acting analogs administered continuously.

For a detailed comparison of how this pulsatile profile differs from the sustained GH elevation produced by CJC-1295 vs Ipamorelin, researchers should review the dedicated comparison guide.

Somatostatin Counterregulation

The pituitary's responsiveness to sermorelin is gated by somatostatin (also called somatotropin release-inhibiting factor, SRIF), which is co-released by hypothalamic neurons and acts on somatostatin receptors (SSTRs) on somatotrophs to inhibit both GH synthesis and release. The timing of sermorelin administration relative to the endogenous somatostatin/GHRH rhythm significantly influences the magnitude of the GH response — a consideration relevant to research dosing protocols. This antagonism with somatostatin is why sermorelin's GH-stimulating effects are context-dependent and can vary substantially between subjects based on their underlying neuroendocrine tone.

FDA Approval History: Geref Diagnostic

Approval and Clinical Indication

Sermorelin (as sermorelin acetate) was approved by the FDA under the brand name Geref Diagnostic (manufactured by Serono) for use as a diagnostic agent in evaluating pituitary GH secretory capacity. The initial approval was for pediatric indications — specifically, to assess whether children with short stature or suspected GH deficiency had adequate pituitary GH reserve. The provocative GH stimulation test using sermorelin involved IV administration followed by serial GH measurements over 45-90 minutes; a peak GH response below 7-10 ng/mL typically prompted further diagnostic workup.

A second sermorelin product, Geref (not the diagnostic formulation), was later evaluated for therapeutic use in adults with GH deficiency, and formulations were investigated for treating growth failure in children and for addressing the GH decline associated with aging (somatopause). The drug received broader attention in the late 1990s as interest in GH-axis modulation for aging research grew.

Voluntary Market Withdrawal

Serono voluntarily withdrew Geref Diagnostic from the US market in 2002, citing commercial rather than safety reasons. This withdrawal did not reflect any identified safety problem with the compound but rather reflected the pharmaceutical company's portfolio decisions amid competition from recombinant human GH products and changes in diagnostic practice patterns. Following withdrawal, sermorelin transitioned primarily into compounding pharmacy formulations and became a widely used tool in research settings.

The withdrawal of Geref Diagnostic is significant for understanding sermorelin's current regulatory status: it is not a controlled substance in the US, and it is not currently the subject of a New Drug Application (NDA). This means its manufacture and distribution are governed by compounding pharmacy regulations and research use designations rather than by standard pharmaceutical approval frameworks.

Regulatory Context for Research Use

For research purposes, sermorelin acetate is classified as a Research Use Only (RUO) reagent when supplied by peptide research companies. This classification means it is intended strictly for in vitro and preclinical research, not for human administration. Researchers should note this designation in all experimental documentation and comply with applicable institutional and regulatory requirements governing peptide research.

Research Evidence

GH Restoration in Aging (Somatopause Research)

One of the most intensively studied applications of sermorelin has been its potential to counteract the age-related decline in GH secretion — a phenomenon sometimes termed somatopause. Growth hormone secretion declines progressively with age, decreasing approximately 14% per decade after young adulthood. By the 7th decade of life, most adults have lost 50-70% of the GH secretory capacity observed in young adults. This decline is accompanied by reductions in circulating IGF-1 levels and is associated with changes in body composition (increased fat mass, decreased lean mass), bone mineral density, and physical function.

Sermorelin's ability to stimulate pituitary GH release makes it a mechanistically attractive intervention for studying whether augmenting the GH axis in older subjects can restore more youthful GH secretory patterns. Key research findings include:

Khorram et al. (1997, Journal of Clinical Endocrinology & Metabolism): This landmark study administered a GHRH analog subcutaneously to older subjects over an extended period. Results showed statistically significant increases in GH pulse amplitude, 24-hour GH secretion (as measured by frequent sampling), and serum IGF-1 concentrations compared to placebo. Subjects also showed improvements in body composition markers including reduced fat mass and maintained or increased lean mass. This study established the principle that the aging pituitary retains the capacity to respond to GHRH-receptor stimulation when provided with adequate ligand, suggesting that somatopause is partly a consequence of reduced hypothalamic GHRH output rather than intrinsic somatotroph failure.

Walker RF (2006, Clinical Interventions in Aging): This review examined the growing body of evidence for GHRH analogs in aging research, including sermorelin, and concluded that chronic GHRH-receptor stimulation could restore more youthful GH secretory profiles in older subjects. The review highlighted that sermorelin's mechanism — working through endogenous regulatory pathways — preserved physiological GH pulse dynamics in a way that exogenous GH replacement did not.

Sleep Architecture Studies: Research has also examined sermorelin's potential effects on sleep-related GH secretion. GH is predominantly secreted during slow-wave sleep (SWS, stages 3-4 NREM), and GH pulses during early-night SWS represent the dominant daily GH secretory event in young adults. Some studies have found that GHRH analog administration before sleep increases slow-wave sleep duration and the associated GH pulse, suggesting that the sleep-GH axis may be partly restored by exogenous GHRH-receptor stimulation. These findings have implications for aging research given that SWS decreases significantly with age and the nocturnal GH pulse diminishes concurrently.

Body Composition Research

Multiple studies have investigated the impact of GH axis stimulation via GHRH analogs on adipose tissue and lean mass. The mechanistic rationale is that GH promotes lipolysis in adipose tissue (particularly visceral fat), stimulates IGF-1 production in the liver (which promotes muscle protein synthesis), and influences glucose metabolism. Research findings with sermorelin in body composition contexts include:

• •Visceral adiposity: Studies examining abdominal fat in older subjects receiving GHRH analog treatment have generally found reductions in visceral fat mass over treatment periods ranging from 6 to 12 months, as measured by CT or DXA
• •Lean mass retention: Lean body mass either increased or was maintained in treatment groups compared to placebo, consistent with the anabolic effects of IGF-1 on skeletal muscle
• •Bone mineral density: Some studies have reported trends toward increased bone mineral density, though this endpoint requires longer treatment periods to show statistical significance given the slow turnover of bone mineral

It is important to note that body composition benefits in clinical research settings were typically modest and required sustained (months-long) treatment protocols. Sermorelin is a GH secretagogue, not a direct anabolic agent — the downstream effects on body composition are mediated through endogenous GH and IGF-1 and are subject to the individual's age, baseline somatotroph function, and overall metabolic state.

Cognitive and Neuroprotective Research

Emerging preclinical and early translational research has explored the potential CNS effects of GHRH-R stimulation. GH and IGF-1 receptors are expressed in multiple brain regions including the hippocampus, hypothalamus, and cerebral cortex. IGF-1 in particular has well-characterized neuroprotective and neurotrophic effects, including promotion of neurogenesis in the hippocampal dentate gyrus and modulation of amyloid-beta clearance pathways.

Animal models have shown that GHRH analog administration can improve performance in spatial memory tasks and support hippocampal neurogenesis, though translation to human models remains an active area of research with considerable uncertainty. These findings are mechanistically plausible given that GH-axis decline with aging correlates temporally with age-related cognitive changes, but causation has not been established in human populations.

IGF-1 as a Research Biomarker

Because sermorelin stimulates endogenous GH release, which in turn drives hepatic IGF-1 production, circulating IGF-1 levels serve as the primary biomarker for GH axis activity in sermorelin research protocols. IGF-1 has a longer half-life (~15-18 hours) compared to GH (~20-30 minutes) and shows much less pulsatile variation, making it a more practical monitoring endpoint than serum GH measurements. Researchers typically use age- and sex-normalized IGF-1 reference ranges to assess whether treatment has produced clinically meaningful GH axis activation.

Sermorelin vs. CJC-1295: Structural and Functional Differences

Structural Modifications in CJC-1295

CJC-1295 is a modified version of GRF(1-29) with four key structural changes designed to extend its half-life:

1. D-Ala at position 2: Replaces L-Ala to confer resistance to DPP-IV cleavage at the Tyr¹-Ala² bond — the primary degradation pathway that limits native sermorelin's half-life

2. Gln-to-Ala substitution at position 8: Reduces susceptibility to asparagine deamidation

3. Ala-to-α-aminoisobutyric acid (Aib) at position 15: Provides conformational stability against enzymatic degradation

4. Leu-to-Arg at position 27: Reduces methionine oxidation vulnerability

The DAC (Drug Affinity Complex) version of CJC-1295 adds a lysine-linked maleimidoproprionic acid group that allows covalent binding to circulating albumin, extending the effective half-life to approximately 6-8 days through the albumin "depot" mechanism. This produces fundamentally different pharmacodynamics compared to sermorelin.

For a broader comparison that includes GHRP-6, MK-677, and Ipamorelin alongside these compounds, see the Growth Hormone Secretagogues Compared guide.

Pharmacokinetic Comparison

Physiological vs. Pharmacological GH Profiles

The most important functional difference between sermorelin and CJC-1295 DAC is the GH secretion pattern they produce. Sermorelin's brief receptor activation produces GH pulses that closely mimic physiological GH secretion — short-duration elevations of GH followed by return to baseline. CJC-1295 DAC, by contrast, produces a sustained, quasi-continuous elevation of GH ("GH bleed") that is distinctly non-physiological.

Whether pulsatile vs. continuous GH signaling produces meaningfully different downstream effects remains a research question. Some evidence suggests that pulsatile GH delivery is more effective at driving hepatic IGF-1 production and may be more metabolically favorable, but these differences may be attenuated at relevant research dose ranges.

Research Application Selection

• •Sermorelin is preferred when: studying the acute GH pulse response, investigating somatostatin/GHRH interactions, modeling physiological GHRH dynamics, or studying phenomena that depend on pulsatile GH secretion
• •CJC-1295 DAC is preferred when: sustained IGF-1 elevation is the research goal, dosing frequency is a practical constraint, or the study design requires consistent trough GH/IGF-1 levels
• •CJC-1295 (no DAC) occupies a middle position: moderately extended half-life (~30 minutes) with preserved pulsatility, often used as an intermediate between sermorelin's very short action and CJC-1295 DAC's prolonged action

Understanding peptide half-life dynamics is fundamental to designing protocols with either compound. The Peptide Half-Life Reference Guide provides detailed pharmacokinetic context for sermorelin and related GHRH analogs.

Research on Combination Protocols

GHRH + GHRP Synergy

One of the most extensively documented phenomena in GH secretagogue research is the synergistic interaction between GHRH analogs (like sermorelin) and GHRH-independent GH secretagogues (GHRPs). GHRPs such as GHRP-6, GHRP-2, and Ipamorelin act through the ghrelin receptor (GHSR-1a) rather than the GHRH-R, stimulating GH release via a complementary pathway. When administered simultaneously, a GHRH analog plus a GHRP produces a GH response that is synergistically greater than the sum of their individual effects — typically 2 to 10 times greater than either compound alone.

The mechanistic basis for this synergy involves:

1. Complementary intracellular signaling: GHRH-R activation increases cAMP/PKA signaling; GHSR-1a activation primarily operates through Gαq/phospholipase C/IP₃/Ca²⁺ pathways. These converge on GH secretion through independent routes.

2. Somatostatin inhibition by GHRPs: GHRPs may reduce hypothalamic somatostatin release, reducing the inhibitory tone on pituitary somatotrophs and amplifying the GHRH response.

3. Enhanced somatotroph sensitivity: Some evidence suggests GHRPs sensitize somatotroph cells to GHRH signaling, enhancing GH response magnitude.

Combination research protocols using sermorelin with ipamorelin, GHRP-6, or GHRP-2 have been studied in both animal models and human clinical contexts, and the synergistic GH response is well-established. These combination approaches are a core theme in the Growth Hormone Secretagogues Compared research overview.

Combination with IGF-1 Pathway Modulators

In preclinical research contexts, sermorelin has been studied in combination with IGF-1 analogs and insulin sensitizers to explore interactions along the GH-IGF-1 axis. These investigations are motivated by the observation that GH resistance (reduced hepatic responsiveness to GH, leading to low IGF-1 despite elevated GH) can limit the downstream benefits of GH secretagogue therapy. Understanding whether sermorelin's effects are limited by post-GH receptor signaling is an active research area.

Safety and Tolerability Profile

Clinical Tolerability Overview

Based on the extensive clinical research conducted during Geref's development and post-approval use, sermorelin demonstrates a favorable safety profile consistent with its mechanism of action through endogenous regulatory pathways. Unlike exogenous GH, which bypasses normal feedback mechanisms and can cause pharmacological GH excess, sermorelin's effects are naturally constrained by somatostatin counterregulation and the downstream IGF-1 negative feedback loop.

Key safety and tolerability observations from clinical research literature:

Injection site reactions: The most commonly reported adverse effect in clinical studies is local injection site reactions, including pain, redness, swelling, or induration at the site of subcutaneous injection. These reactions are generally mild, transient, and self-limiting, and do not typically require discontinuation of treatment.

Headache: Transient headache has been reported in some subjects following sermorelin administration, possibly related to the brief changes in cerebral blood flow associated with GH and IGF-1 release. Severity is generally mild.

Flushing and dizziness: Occasional reports of transient flushing (particularly facial) and dizziness have been noted, likely related to the vasoactive effects of GH and the acute hormonal changes following administration.

Nausea: Mild nausea has been reported infrequently and is typically brief.

Theoretical Safety Advantages Over Exogenous GH

Researchers have theorized that sermorelin's indirect mechanism confers safety advantages over direct GH administration in several areas:

1. No supraphysiological GH levels: The somatostatin/negative feedback axis prevents GH from exceeding physiological ranges under sermorelin treatment, unlike with exogenous GH where dose-dependent GH excess is possible

2. Preservation of pulsatility: Physiological GH pulses are associated with normal receptor sensitivity; continuous GH elevation (as with exogenous GH) can lead to receptor downregulation

3. No suppression of endogenous GHRH signaling: Exogenous GH suppresses endogenous GHRH and GH secretion through negative feedback; sermorelin works with the existing system rather than replacing it

4. Reduced aromatization-related effects: Lower peak GH levels compared to pharmacological GH replacement may reduce peripheral aromatization and estrogen-related side effects in some subjects

Contraindications and Research Exclusion Criteria

In clinical research and diagnostic use, sermorelin has been contraindicated in subjects with:

• •Known hypersensitivity to sermorelin or any component of the formulation
• •Active malignancy (due to the growth-stimulating effects of GH/IGF-1 on tumor cells)
• •Hypothyroidism uncorrected by thyroid hormone replacement (thyroid hormones are required for full GH axis function)

These exclusion criteria reflect both the mechanism of action (GH/IGF-1 axis stimulation) and standard clinical research ethics practices.

Pediatric Safety Considerations

The FDA-approved use of Geref Diagnostic in pediatric subjects for GH stimulation testing was associated with a generally favorable safety profile in that population as well. Post-injection transient facial flushing was occasionally observed. No serious adverse events attributable to sermorelin were identified in the diagnostic testing context, where single-dose IV administration was used.

Research Dosing Protocols (Research Context Only)

The following information is provided for scientific reference and describes dosing protocols used in published clinical research. It does not constitute medical advice and is not intended for human therapeutic use outside of supervised clinical settings.

Historical Research Dosing Parameters

Published research studies examining sermorelin for GH restoration in aging and body composition have used varying dose ranges and administration schedules. Common parameters from the literature include:

Dose range: 0.2–0.3 μg/kg/day to 2 μg/kg/day administered subcutaneously, with some studies using fixed doses in the range of 20–50 μg per injection. Contemporary research protocols have also referenced fixed doses of 200–500 mcg subcutaneously administered before sleep — a range that balances adequate GHRH-R stimulation against somatostatin counterregulation and aligns with the nocturnal GH secretory window (Vittone et al., 1997, Metabolism, PMID 9005976; Corpas et al., 1993, J Clin Endocrinol Metab, PMID 8421077).

Administration timing: Evening or bedtime administration has been favored in research protocols to coincide with the dominant nocturnal GH secretory window and to leverage the synergy between exogenous GHRH stimulation and sleep-associated GH secretion

Frequency: Research protocols have ranged from once-daily (QD) to three-times-daily (TID) subcutaneous administration, with more frequent dosing protocols designed to better approximate physiological GHRH pulsatility

Study durations: Most body composition and GH restoration studies have used treatment periods of 6-12 months to allow sufficient time for detecting changes in IGF-1, lean mass, and fat mass

Research Monitoring Parameters

In clinical research settings, the following monitoring parameters have been used:

• •Serum IGF-1: Primary biomarker for GH axis activation; measured fasting in morning blood draws; evaluated against age- and sex-normalized reference ranges
• •Fasting insulin/glucose: To assess any effects on glucose metabolism (GH promotes insulin resistance at pharmacological doses)
• •Thyroid function (TSH, free T4): Hypothyroidism blunts the pituitary GH response; baseline assessment is standard
• •Cortisol/ACTH: In diagnostic protocols, concurrent assessment of other pituitary axes is typical
• •Complete blood count and comprehensive metabolic panel: Standard safety monitoring

Dose-Response Relationship

Research suggests a dose-response relationship between sermorelin dose and the resultant GH secretory response, with diminishing returns at higher doses likely reflecting somatostatin counterregulation. The GH response magnitude is also highly variable between subjects, influenced by age, BMI (adiposity blunts the GH response), baseline IGF-1 status, and time since last food intake. Researchers using sermorelin as a provocative agent should be aware that standardized fasting conditions and consistent timing are important for result reproducibility.

Research Specifications and Laboratory Handling

Physical and Chemical Properties

Storage and Stability

Lyophilized (unreconstituted) powder:

• •Long-term storage: –20°C to –80°C in a frost-free freezer
• •Avoid repeated freeze-thaw cycles; aliquot before first use
• •Keep desiccated and protected from light
• •Shelf life at –20°C: typically 12-24 months from date of synthesis when stored properly

Reconstituted solution:

• •Short-term storage (up to 2-4 weeks): 2-8°C (refrigerator, not frozen)
• •Reconstituted peptide is more susceptible to degradation than lyophilized form
• •Avoid exposure to elevated temperatures, direct light, or agitation
• •Use bacteriostatic water (0.9% benzyl alcohol) for reconstitution when extended refrigerated use is planned; sterile water for immediate use
• •Discard if solution appears cloudy, discolored, or particulate

Primary degradation pathways:

• •N-terminal DPP-IV cleavage (enzymatic degradation in solution)
• •Aspartic acid residue isomerization (chemical degradation at Asp³)
• •Methionine oxidation at Met²⁷ (particularly with exposure to peroxide-containing solvents)

Reconstitution Protocol (Research Use)

For standard research use, sermorelin is typically reconstituted to a stock concentration of 1-2 mg/mL using bacteriostatic water or sterile acetic acid (0.1-1% acetic acid solution). The peptide dissolves readily. After reconstitution, gently swirl (do not vortex) to ensure complete dissolution. Transfer to sterile storage vials if aliquoting.

For calculating reconstitution volumes, researchers may find the peptide dosing calculator helpful for converting between mass-based (μg) and volume-based (mL) measurements.

Regulatory and Research Compliance Framework

Current Regulatory Status

In the United States, sermorelin acetate is not currently approved for any therapeutic indication following the voluntary withdrawal of Geref Diagnostic. Its current availability falls into two categories:

1. Compounding pharmacy formulations: Compounding pharmacies may produce sermorelin formulations under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act for specific patient prescriptions, subject to state pharmacy board regulations and FDA oversight. The FDA has periodically reviewed which substances may be compounded; researchers and clinicians should verify the current status.

2. Research use only (RUO) peptide supply: Peptide research companies supply sermorelin acetate under RUO designation for in vitro and preclinical research purposes. RUO material is not manufactured under pharmaceutical GMP standards (though many reputable suppliers maintain comparable quality controls) and is not intended for human administration. Consult verified researcher reviews to identify sermorelin vendors with strong documentation practices.

Certificate of Analysis (CoA) and Quality Control

For research purposes, sermorelin obtained from reputable suppliers should be accompanied by a Certificate of Analysis (CoA) documenting:

• •Identity confirmation (mass spectrometry, typically MALDI-ToF or LC-MS/MS)
• •Purity assessment (HPLC, typically >98% for research-grade material)
• •Microbial testing (for sterile formulations)
• •Endotoxin testing (LAL assay, particularly for in vivo research use)

Researchers can read community supplier reviews to identify vendors with consistently strong CoA documentation before purchasing.

Verifying these quality parameters before use is essential for reproducible research outcomes and for ensuring that observed biological effects reflect sermorelin's activity rather than contaminating impurities.

Related Compounds and Research Ecosystem

Primary GHRH Analog Comparators

Researchers working with sermorelin in the GHRH analog class should be familiar with the following related compounds:

Tesamorelin (TH9507): A fully stabilized GHRH(1-44) analog with a trans-3-hexenoic acid conjugated to the N-terminus, providing resistance to DPP-IV cleavage while maintaining the full-length GHRH sequence. FDA-approved for HIV-associated lipodystrophy under the brand name Egrifta. Half-life approximately 30-40 minutes. Tesamorelin is the only currently approved GHRH analog in the US market.

CJC-1295 (no DAC) / Modified GRF(1-29): As described above, the D-Ala²-modified version of GRF(1-29) with extended half-life (~30 minutes) and DPP-IV resistance. Often used interchangeably with sermorelin in protocols where moderately extended action is preferred.

CJC-1295 DAC: The albumin-binding version with ~6-8 day half-life. Provides sustained GH elevation through a pharmacologically distinct mechanism.

Examorelin (GHRP-6) and Ipamorelin: These are ghrelin receptor agonists (GHRPs), not GHRH analogs, but they are frequently used in combination with sermorelin due to the synergistic GHRH + GHRP interaction. See CJC-1295 vs Ipamorelin for comparative details.

GHS-R (Ghrelin Receptor) vs. GHRH-R Comparison

Sermorelin acts exclusively at the GHRH-R, while GHRPs and ghrelin act at the GHS-R (also called GHSR-1a). These two receptor systems are complementary co-regulators of GH secretion, and research protocols frequently leverage both pathways simultaneously to maximize GH output. The pharmacological interaction between GHRH-R and GHS-R agonism has been characterized as synergistic rather than simply additive across multiple species and experimental systems.

Research Disclaimer

Sermorelin is supplied and sold exclusively for research use only (RUO). This article is intended for scientific education and research information purposes only. Sermorelin is not approved by the FDA for human therapeutic use outside of historical diagnostic indications that have been voluntarily withdrawn from the market. This information does not constitute medical advice, and sermorelin should not be used for self-administration or any human therapeutic application. All research involving sermorelin should be conducted in compliance with applicable institutional, local, state, and federal regulations governing peptide research and GH-axis modulation studies.

---

For researchers evaluating the broader landscape of growth hormone secretagogues, see Growth Hormone Secretagogues Compared. For half-life and pharmacokinetic reference data across the GHRH analog class, see the Peptide Half-Life Reference Guide. Dosing calculations can be performed with the Research Calculator. For GLP-1 receptor agonist research, see the Semaglutide Research Overview. To compare sermorelin suppliers and pricing by vendor, purity, and price, visit the Sermorelin Supplier Comparison or the Peptides.SO Compare Hub.

---

Further Reading:

• •CJC-1295 DAC: Long-Acting Growth Hormone-Releasing Hormone Analog
• •GHRP-6: The Original Growth Hormone Releasing Peptide — Complete Research Profile
• •Tesamorelin: Stabilized GHRH Analog for Metabolic and Body Composition Research
• •Ghrelin: The Acylated Gastric Peptide Driving Growth Hormone, Energy Homeostasis, and Neuroprotection Research
• •Reconstitution Calculator
• •Peptide Stack Builder

Live Research Peptide Pricing Snapshot: Sermorelin (2026)

Sermorelin is one of the most heavily stocked compounds tracked on Peptides.SO. Live data across 79 active suppliers and 133 in-stock offers:

With one of the deepest supplier pools on the platform, sermorelin pricing is tightly clustered relative to lower-volume compounds — a strong signal of commoditization at the research-grade tier. Full live comparison: Sermorelin price listing.

Frequently Asked Questions

Did sermorelin ever have FDA approval?

Yes — sermorelin acetate was FDA-approved as Geref for diagnostic evaluation of growth hormone secretion and later for adult-onset GH insufficiency management, though the branded product was voluntarily withdrawn from the market for commercial reasons, not safety findings (Clinical Interventions in Aging, PMID 18046908). It is now sourced exclusively as a research use only (RUO) compound.

How was sermorelin studied in pediatric populations?

Sermorelin has a substantial pediatric literature base from its use in diagnosing and researching idiopathic growth hormone deficiency in children prior to the Geref withdrawal (BioDrugs, PMID 18031173).

Is sermorelin being studied outside the GH axis?

Yes — emerging research has explored sermorelin in oncology contexts, including a case report on recurrent glioma (Annals of Translational Medicine, PMID 33842627), reflecting the broader GHRH-receptor research interest beyond classic somatotropic applications.

How does sermorelin's price compare to CJC-1295?

Sermorelin's deep supplier pool (79 vendors) generally makes it more competitively priced at the median than longer-acting GHRH analogs, though direct comparison depends on the specific CJC-1295 formulation (with or without DAC). See the Sermorelin vs. CJC-1295 section above for the structural and pharmacokinetic comparison.

What purity should researchers expect from sermorelin listings?

Research-grade sermorelin should carry HPLC purity documentation, typically ≥98%. See the Certificate of Analysis section above for the full quality-verification checklist.

**Where can I compare current sermorelin prices across vendors?

The Sermorelin comparison page lets you compare sermorelin pricing across multiple verified suppliers side by side, with real-time stock availability and purity certificates.**

The live Sermorelin listing page tracks all 79 active suppliers with continuously updated pricing.